RxDoctor Payments Data

Inderpal Gujral, MD

Cardiovascular Disease · Laguna Hills, CANPI 1063416410

Payments from drug & device makers

$10,707in general payments, 2019–2025

Across 67 payments — averaging $159.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$8K
  • Medtronic$1K
  • Novartis$765
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$476
  • Abbott$152
  • Kiniksa Pharmaceuticals, Ltd.$122
  • plus $468 from 8 others

What the payments were for

  • Consulting fees$1852%
  • Speaking & faculty fees$7,65977%
  • Travel & lodging$1,01910%
  • Food & beverage$1,07911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,707 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$335,665
Medicare patients
1,821
Services billed
4,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$53,424
XareltoRivaroxaban33$31,450
EntrestoSacubitril/Valsartan15$14,610
Furosemide84$622
Amlodipine Besylate29$407
Metoprolol Tartrate52$339
Digoxin25$280
Diltiazem Hcl12$263
Metoprolol Succinate20$257
Potassium Chloride15$224
Carvedilol33$190
Amiodarone Hcl11$190
Isosorbide Mononitrate ErIsosorbide Mononitrate12$155
ClopidogrelClopidogrel Bisulfate13$121
Lisinopril34$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$765$14,61015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →